



New Directions in Leukaemia Research 2018 Meeting
25 - 28 March 2018
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Program updated 13/02/2018

Start	Finish	SUNDAY 25 MARCH 2018	Start	Finish
11:00	18:30	Registration Opens	11:00	18:30
Plaza P9 & P10				
13:00	13:15	<p align="center">Welcome and Conference Opening Ross Dickins & Matt McCormack (Conference Co-Chairs)</p>	13:00	13:15
13:15	15:15	<p align="center">Session 1 - Epigenetics Sponsored by Celgene</p>	13:15	15:15
Plaza P9 & P10				
13:15	14:00	<p align="center">Margaret (Peggy) Goodell Baylor College of Medicine, Houston, USA</p>	13:15	14:00
14:00	14:30	<p align="center">Mark Dawson Peter MacCallum Cancer Centre, AUS</p>	14:00	14:30
14:30	14:45	<p align="center">Madison Kelly 53: BCOR regulates myeloid differentiation and leukaemogenesis by altering the epigenome</p>	14:30	14:45
14:45	15:00	<p align="center">Charles Bell 27: Enhancer remodeling overcomes therapeutic resistance driven by non-genomic evolution in cancer</p>	14:45	15:00
15:00	15:15	<p align="center">Luisa Cimmino 55: Restoration of TET function as a therapeutic strategy in leukemia</p>	15:00	15:15
15:15	16:00	Afternoon Tea	15:15	16:00
16:00	18:15	<p align="center">Session 2 - Lymphoid Malignancies: ALL & CLL Sponsored by abbvie</p>	16:00	18:15
Plaza P9 & P10				
16:00	16:45	<p align="center">Iannis Aifantis NYU School of Medicine, New York, USA</p>	16:00	16:45
16:45	17:15	<p align="center">Mary Anne Anderson Walter and Eliza Hall Institute, AUS</p>	16:45	17:15
17:15	17:30	<p align="center">Charles de Bock 2: Activated JAK-STAT Signaling Cooperates with HOXA9 And Drives Leukemia Development</p>	17:15	17:30
17:30	17:45	<p align="center">Sebastien Malinge 15: A murine knock-In model for the JAK3A572V activating mutation provides insights into pathobiology and therapy of T cell hematopoietic disorders</p>	17:30	17:45
17:45	18:15	<p align="center">John Seymour Peter MacCallum Cancer Centre, Melbourne, AUS Clinical Spotlight: Chronic Lymphocytic Leukemia</p>	17:45	18:15
Welcome Reception				



New Directions in Leukaemia Research 2018 Meeting
25 - 28 March 2018
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Program updated 13/02/2018

Start	Finish	MONDAY 26 MARCH 2018	Start	Finish
7:00	19:00	Registration Opens	7:00	19:00
7:15	8:15	New Investigator "Meet the Expert" Breakfast Session Convenors: Catherine Carmichael & Jess Salmon	7:15	8:15
8:30	10:30	Session 3 - Stem Cells	8:30	10:30
Plaza P9 & P10				
8:30	9:15	Dominique Bonnet Francis Crick Institute, London, UK	8:30	9:15
9:15	10:00	Atsushi Iwama Chiba University, JPN	9:15	10:00
10:00	10:15	Tina Schnoeder 32: Myeloid Leukemia Stem Cells Depend on Phospholipase C Gamma 1 (Plcg1) Signaling	10:00	10:15
10:15	10:30	Matthew McCormack 68: Lmo2 is dispensable for established Lmo2-induced T-cell acute lymphoblastic leukaemia (T-ALL) in mice	10:15	10:30
10:30	11:00	Morning Tea & Trade Display	10:30	11:00
11:00	13:15	Session 4 - Myelodysplastic Syndrome & Acute Myeloid Leukaemia Sponsored by Celgene	11:00	13:15
Plaza P9 & P10				
11:00	11:45	Kimberly Stegmaier Clinical Translation of AML Genomics	11:00	11:45
11:45	12:15	Paula Mariton Clinical Spotlight: Acute Myeloid Leukemia	11:45	12:15
12:15	12:45	Nikki Verrills University of Newcastle, AUS	12:15	12:45
12:45	13:00	Lev Kats 63: PRC2 and H3K27Me3-dependent regulation of gene expression by mutant IDH2 in AML	12:45	13:00
13:00	13:15	Ashwin Unnikrishnan 65: AZA-MS: a novel multiparameter method uncovers the intracellular dynamics of Azacitidine therapy in vivo	13:00	13:15
13:15	13:45	Lunch & Trade Display	13:15	13:45
Plaza P9 & P10				
13:45	14:45	New Investigator Forum – Career Development (Plaza P9&10) Convenors: Catherine Carmichael & Jess Salmon Sponsored by the Leukaemia Foundation Australia	13:45	14:45
14:45	15:15	Afternoon Tea & Trade Display	14:45	15:15
15:15	16:15	Session 5 - Donald Metcalf Oration - Introduced by Andrew Roberts	15:15	16:15
Plaza P9 & P10				
15:15	16:15	John Rasko Royal Prince Alfred Hospital, AUS	15:15	16:15
16:15	16:45	Poster Preview Session	16:15	16:45
16:45	18:45	Poster Session & Trade Display	16:45	18:45



New Directions in Leukaemia Research 2018 Meeting
25 - 28 March 2018
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Program updated 13/02/2018

Start	Finish	TUESDAY 27 MARCH 2018	Start	Finish
8:00	18:00	Registration Opens	8:00	18:00
8:30	10:45	Session 6 - Cell Therapy & Immunotherapy <i>Sponsored by Novartis</i>	8:30	10:45
Plaza P9 & P10				
8:30	9:15	Stephen Ansell Mayo Clinic, Minnesota, USA	8:30	9:15
9:15	10:00	Bruce Levine Perelman School of Medicine, University of Pennsylvania, USA	9:15	10:00
10:00	10:30	Marie Bleakley Fred Hutchinson Cancer Research Center, Seattle, USA	10:00	10:30
10:30	10:45	Rebecca Austin 50: Immune responses to acute myeloid leukaemia	10:30	10:45
10:45	11:15	Morning Tea & Trade Display	10:45	11:15
11:15	12:45	Session 7 - Myeloproliferative Neoplasms including CML <i>Sponsored by Bristol-Myers Squibb</i>	11:15	12:45
Plaza P9 & P10				
11:15	11:45	Timothy Hughes South Australian Health and Medical Research Institute, AUS	11:15	11:45
11:45	12:15	Carl Walkley St Vincent's Institute, AUS	11:45	12:15
12:15	12:30	Stefan Eugen Sonderegger 47: Inhibition of PRMT5 effects malignant erythroid differentiation and survival of Jak2V617F mutant precursors in myeloproliferative neoplasms.	12:15	12:30
12:30	12:45	Sebastien Jacquelin 14: In vivo CRISPR editing of Dnmt3a in Jak2V617F Hematopoietic Stem Cells Induces Myelofibrosis through epigenetic reprogramming	12:30	12:45
12:45	13:00	NDLR 2018 Group Photo	12:45	13:00
13:00	14:00	Lunch & Trade Display	13:00	14:00
14:00	15:15	Session 8 - Lymphoma	14:00	15:15
Plaza P9 & P10				
14:00	14:30	Chan Cheah Sir Charles Gairdner Hospital, AUS Clinical Spotlight: Lymphoma	14:00	14:30
14:30	15:00	Gemma Kelly Walter and Eliza Hall Institute, AUS	14:30	15:00
15:00	15:15	Maher Gandhi 25: The Tumor Microenvironment is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma	15:00	15:15
15:15	15:30	Suzanne Cory 73: MYC-driven cells need MNT	15:15	15:30
15:30	16:00	Afternoon Tea & Trade Display	15:15	15:45
16:00	16:45	Session 9 - Myeloma	15:45	16:45
Plaza P9 & P10				
16:00	16:30	Andrew Spencer Monash University, AUS Clinical Spotlight: Myeloma	15:45	16:15
16:30	16:45	Kimberley Clark 13: The role of the protein Gremlin1 in the bone marrow microenvironment in Multiple Myeloma: there are Gremlins in the system	16:30	16:45
16:45	17:00	Kyohei Nakamura 3: IL-18 critically drives immunosuppression in the multiple myeloma microenvironment	16:45	17:00
17:00	18:00	Equity in Science Forum (Plaza P9&10) Convenors: Gemma Kelly & Ingrid Winkler	17:00	18:00
18:15	19:00	Pre-dinner Drinks	18:15	19:00
19:00	23:00	Conference Dinner	19:00	23:00



New Directions in Leukaemia Research 2018 Meeting
25 - 28 March 2018
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Program updated 13/02/2018

Start	Finish	WEDNESDAY 28 MARCH 2018	Start	Finish
8:00	13:00	Registration Opens	8:00	13:00
8:30	10:30	Session 10 - Genomics	8:30	10:15
Plaza P9 & P10				
8:30	9:15	Charles Mullighan St Jude Children's Research Hospital, Memphis, USA	8:30	9:15
9:15	9:45	Anna Brown SA Pathology, Adelaide, AUS	9:15	9:45
9:45	10:00	Susan Heatley 64: Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing.	9:45	10:00
10:00	10:15	Edward Chew 100: Loss of MBD4 predisposes to familial AML with a unique mutational signature.	10:00	10:15
10:15	10:30	Pieter Van Vlierberghe 41: Oncogenic activation and therapeutic targeting of PIM1 in T-ALL and T-LBL	10:15	10:30
10:30	11:00	Morning Tea & Trade Display	10:30	11:00
11:00	13:00	Session 11 - New Therapeutic Approaches	11:00	13:00
Plaza P9 & P10				
11:00	11:30	Scott Lowe Memorial Sloan Kettering Cancer Center, New York, USA	11:00	11:30
11:30	12:00	Ingrid Winkler Mater Institute, AUS	11:30	12:00
12:00	12:30	Michelle Henderson Children's Cancer Institute, AUS	12:00	12:30
12:30	12:00	Fiona Brown 82: MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia	12:30	12:00
12:45	13:00	Gretchen Poortinga 93: BET protein inhibition sensitises ribosomal DNA to localised damage and provides a robust synergistic therapeutic strategy for treating AML	12:45	13:00
12:30	13:00	Conference Close & Prize Presentations Ross Dickins & Matt McCormack (Conference Co-Chairs)	12:30	13:00
13:00	14:00	Lunch & Trade Display	13:00	14:00